Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
YM BioSciences
September 22, 2016
Bubble stocks top the takeover premium charts
September 07, 2016
How Gilead could go back to basics
December 17, 2015
Galapagos turns the tables on AbbVie, courtesy of Gilead
May 07, 2015
Gilead deal shows desire to put oncology at centre of post-Hep C strategy
January 24, 2014
Deal metrics climb in 2013 but big pharma stays away from M&A
October 01, 2013
Therapeutic focus – New agents nip at Jakafi’s heels in myelofibrosis
December 12, 2012
Gilead hopes acquisition JAKs up oncology pipeline
February 27, 2012
YM ready for long haul with myelofibrosis candidate
December 14, 2011
YM gets boost out of ASH results
October 06, 2011
Therapeutic Focus - Poor progress in pancreatic cancer
January 04, 2011
Deals and financing over the Christmas period
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
February 10, 2021
2020 wins top of the froths for biotech stocks
October 04, 2018
Biotech flotations remain in high demand
February 04, 2021
Glaxo’s growth problem
January 27, 2021
Go or no go? Oncology decisions ahead for the FDA
February 05, 2021
Pfizer reveals its PD-1 secret
